Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Hershey Co — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Hershey Co trades at $174.78 (market cap $35.23B). The key difference: Hershey Co pays a 3.34% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Hershey Co nearer its low. Which is the better fit depends on your goals.
| ARKG | HSY | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $236.28 |
52-Week Low | $23.09 | $162.31 |
Market Cap | — | $35.23B |
Enterprise Value | — | $40.03B |
Dividend Yield | — | 3.34% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
HSY trades at $173.66, up 1.17% with recent earnings beats and easing cocoa costs supporting fundamentals. Technicals are bearish with resistance at $175, while valuation metrics like a P/E of 32.34 suggest premium pricing. The company maintains strong cash flow and a 3.22% dividend yield, with Q2 2026 earnings due July 30, 2026, as a key catalyst.
Outlook: Upside exists to the $210.33 consensus target if margin recovery continues, but high debt and volatile input costs pose risks. Analyst sentiment is cautious with 65.7% hold ratings, reflecting balanced growth and valuation concerns amid competitive pressures.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →